Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024

    Nandini Piramal, Chairperson, Piramal Pharma Limitedsaid, " We continue to build on our improved performance in FY24 with 14% YoY revenue growth in Q3 along with a significant improvement in EBITDA margin. Our CDMO business is delivering healthy growth with robust order inflows, especially for differentiated offerings and innovation related work. Our Inhalation Anesthesia portfolio is registering good volume growth in our key market of US and is also seeing increasing traction in ROW...

 

Nandini Piramal, Chairperson, Piramal Pharma Limited said, "We continue to build on our improved performance in FY24 with 14% YoY revenue growth in Q3 along with a significant improvement in EBITDA margin. Our CDMO business is delivering healthy growth with robust order inflows, especially for differentiated offerings and innovation related work. Our Inhalation Anesthesia portfolio is registering good volume growth in our key market of US and is also seeing increasing traction in ROW markets. Our India Consumer Healthcare business is delivering steady growth driven by our power brands and contribution from new product launches.

On the sustainability front, we have taken significant reduction targets for our Scope 1, 2 and 3 GHG emissions by FY2030. We are also working on multiple initiatives in the areas of water conservation, responsible waste disposal, gender diversity, employee safety, sustainable supply chain and community development.  

We look forward to continuing our momentum in Q4 and end the financial year on a positive note."

Key Business Highlights for Q3FY24 and 9MFY2

Contract Development and Manufacturing Organization (CDMO):

Complex Hospital Generics (CHG):

India Consumer Healthcare (ICH):

*New development and commercial orders. These are over and above the existing multi-year manufacturing relationships

 

 

 

Q3 and 9M FY2024 Earnings Conference Call

Piramal Pharma Limited will be hosting a conference call for investors / analysts on 31^st January 2024 from 5:00 PM to 5:45 PM(IST)to discuss its Q3 and 9M FY2024 Results.

The dial-in details for the call are as under:

 

About Piramal Pharma Ltd:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter products. In addition, one of PPL's associate companies, AbbVie Therapeutics India Private Limited (formerly Allergan India Pvt Ltd), a joint venture between Allergan (now part of AbbVie) and PPL, has emerged as one of the market leaders in the ophthalmology therapy area. Further, PPL has a minority investment in Yapan Bio Private Limited. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.

For more information visit: www.piramaI.com/pharmaI Twitter.

Logo - https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q3-and-9m-fy2024-302048384.html